SGS Acquires CMIC to Boost US Bioanalytical Capacity

SGS has acquired CMIC, INC., a Chicago-based bioanalytical testing specialist, marking the global testing, inspection and certification group’s second US laboratory acquisition in as many months. Announced on 8 June 2026, the deal advances SGS’s Strategy 27 plan to double North American sales between 2023 and 2027, and strengthens its capabilities across biologics, gene therapies and oligonucleotides. Financial terms were not disclosed. The pace signals an accelerating SGS push into North American bioanalytical infrastructure.

Established in 2010, CMIC, INC. supports North American pharmaceutical and biotech manufacturers bringing specialised biologics and therapeutics to market. Its 27,000 square foot GLP-compliant facility delivers bioanalysis across both pre-clinical and clinical phases of the drug development lifecycle and is geared for high-volume projects with rapid turnaround. The acquisition strengthens SGS’s ability to support drug development across complex molecule therapies including biologics, gene therapies and oligonucleotides, all modalities that require highly specialised analytical methods and face stringent oversight from the FDA, Health Canada and other regulators.

CMIC, INC. is a group company of Japan-listed CMIC Holdings Co., Ltd., which will continue to collaborate with SGS through its CMIC Pharma Science analytical laboratories arm in Japan. Joseph Bower, Head of Life Sciences at SGS North America, said the deal strengthens the group’s ability to deliver bioanalytical data supporting the safety and efficacy of complex molecule therapies in a region where demand for advanced, high-precision capabilities continues to grow. The CMIC site joins an SGS network of more than 20 bioanalytical laboratories across 11 countries, including 10 GLP-compliant sites.

The doubling-down on US bioanalytical capacity in such a short window is the more interesting strategic signal here. With biologics, gene therapies and oligonucleotides driving outsourced testing demand and the wider CRO market under pricing pressure, SGS is buying scale in a specialised, regulated niche where switching costs are high and consolidation is likely to accelerate through the remainder of 2026.